Case report of tuberculous peritonitis in a patient with psoriasis using interleukin-17 A inhibitors
10.13699/j.cnki.1001-6821.2023.23.029
- VernacularTitle:银屑病患者应用白细胞介素-17A抑制药发生结核性腹膜炎的病例分析
- Author:
Jing DONG
1
;
Xu-Zhu MA
;
Xiao-Hui WANG
;
Ming-Gui LIN
Author Information
1. 北京清华长庚医院感染性疾病科,北京 102218
- Keywords:
secukinumab;
interleukin-17 A inhibitor;
mycobacterium tuberculosis;
extrapulmonary tuberculosis;
psoriasis
- From:
The Chinese Journal of Clinical Pharmacology
2023;39(23):3479-3481
- CountryChina
- Language:Chinese
-
Abstract:
Secukinumab,a novel interleukin-17A(IL-17A)inhibitor biologic agent,is approved for treating psoriasis,ankylosing spondylitis,and related conditions.Its downstream effects on inflammatory pathways have minimal impact on infectious diseases,making it relatively safe for clinical use.To our knowledge,there are currently no reports of secukinumab activating latent tuberculosis infections into active tuberculosis.However,this report presents a case of tuberculous peritonitis that developed after 11 months of secukinumab therapy for psoriasis,emphasizing the importance of monitoring potential adverse events associated with its use,particularly in patients with underlying risk factors for latent tuberculosis infections.
